Markets:

Overview

News

Currencies

International

Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

26.43 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Maze Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight ↗

Today 10:55 EDT

Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest.

Via MarketBeat

Gapping stocks in Tuesday's session ↗

September 22, 2026

Via Chartmill

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 ↗

September 11, 2026

The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high.

Via The Motley Fool

Topics Regulatory Compliance

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 09, 2026

Via Chartmill

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? ↗

June 29, 2026

This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? ↗

June 05, 2026

This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.

Via The Motley Fool

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials ↗

May 07, 2026

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. ↗

April 04, 2026

This clinical-stage biotech focused on precision medicines for kidney and metabolic diseases just reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗

March 25, 2026

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 25, 2026

Via Chartmill

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗

March 21, 2026

This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗

February 18, 2026

a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise...

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗

February 16, 2026

Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗

February 01, 2026

Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical...

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗

January 07, 2026

This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings.

Via The Motley Fool

Topics Regulatory Compliance

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗

September 17, 2025

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

Via MarketBeat

What's going on in today's session ↗

September 11, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗

September 11, 2025

Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 11, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

September 11, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗

September 11, 2025

Via Benzinga

Thursday's session: gap up and gap down stocks ↗

September 11, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗

September 11, 2025

Shares catapulted Thursday after its experimental treatment for a rare, genetic disease blew past expectations.

Via Investor's Business Daily

Discover the top movers in Thursday's pre-market session. ↗

September 11, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 11, 2025

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.